In­tel­lia’s gene edit­ing ther­a­py suc­ceeds in Phase 2 ge­net­ic swelling con­di­tion study

In­tel­lia Ther­a­peu­tics’ CRISPR-based treat­ment for a rare ge­net­ic dis­ease called hered­i­tary an­gioede­ma re­duced the bouts of swelling as­so­ci­at­ed with the dis­ease in a mid-stage test …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER